Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence
Purpose: The association of adipose tissue-derived injectable products with platelet-rich plasma (PRP) has been promoted for osteoarthritis (OA) treatment. The aim of this study was to investigate the preclinical and clinical evidence supporting the potential of this combined approach to treat OA....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2024-11-01
|
| Series: | EFORT Open Reviews |
| Subjects: | |
| Online Access: | https://eor.bioscientifica.com/view/journals/eor/9/11/EOR-24-0050.xml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171153962369024 |
|---|---|
| author | Simone Orazi Angelo Boffa Manuela Salerno Lucia Angelelli Stefano Zaffagnini Giuseppe Filardo |
| author_facet | Simone Orazi Angelo Boffa Manuela Salerno Lucia Angelelli Stefano Zaffagnini Giuseppe Filardo |
| author_sort | Simone Orazi |
| collection | DOAJ |
| description | Purpose: The association of adipose tissue-derived injectable products with platelet-rich plasma (PRP) has been promoted for osteoarthritis (OA) treatment. The aim of this study was to investigate the preclinical and clinical evidence supporting the potential of this combined approach to treat OA.
Methods: A systematic review was performed in January 2024 on five databases (PubMed, Embase, Scopus, Cochrane, and Web-of-Science) to identify preclinical in vivo and clinical studies. Safety, OA biomarker changes, and outcomes in terms of clinical and imaging results were analyzed. The quality of studies was assessed with the SYRCLE’s tool for preclinical studies and the Downs and Black checklist for clinical studies.
Results: Ten preclinical studies (223 animals) and 14 clinical studies (594 patients) were included. Preclinical results documented improvements at the cartilage histological and immunohistochemical evaluation and at the biomarkers level. Clinical studies confirmed the procedure’s safety, and the case series suggested satisfactory results in different joints in terms of symptoms and function improvement, with positive findings at the biomarker level. However, the randomized controlled trials did not document any clinical benefit, nor any changes in the imaging analysis. A large heterogeneity and overall poor quality were documented in both preclinical and clinical studies.
Conclusions: There is an increasing interest in the use of adipose tissue-derived injectable products associated with PRP for the treatment of OA joints, with preclinical studies showing promising results with this combined approach. However, clinical studies did not confirm the benefits offered by PRP augmentation to adipose tissue-derived injectable products in patients affected by OA. |
| format | Article |
| id | doaj-art-e8e8cdc1a8ae4a4bb8d79b1258a81c65 |
| institution | Kabale University |
| issn | 2058-5241 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | EFORT Open Reviews |
| spelling | doaj-art-e8e8cdc1a8ae4a4bb8d79b1258a81c652024-11-11T07:04:33ZengBioscientificaEFORT Open Reviews2058-52412024-11-0191110231033https://doi.org/10.1530/EOR-24-0050Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidenceSimone Orazi0Angelo Boffa1Manuela Salerno2Lucia Angelelli3Stefano Zaffagnini4Giuseppe Filardo5Clinica Ortopedica e Traumatologica II, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyClinica Ortopedica e Traumatologica II, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyApplied and Translational Research (ATR) Center, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyClinica Ortopedica e Traumatologica II, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyClinica Ortopedica e Traumatologica II, IRCCS Istituto Ortopedico Rizzoli, Bologna, ItalyDepartment of Surgery, Service of Orthopaedics and Traumatology, EOC, Lugano, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland Purpose: The association of adipose tissue-derived injectable products with platelet-rich plasma (PRP) has been promoted for osteoarthritis (OA) treatment. The aim of this study was to investigate the preclinical and clinical evidence supporting the potential of this combined approach to treat OA. Methods: A systematic review was performed in January 2024 on five databases (PubMed, Embase, Scopus, Cochrane, and Web-of-Science) to identify preclinical in vivo and clinical studies. Safety, OA biomarker changes, and outcomes in terms of clinical and imaging results were analyzed. The quality of studies was assessed with the SYRCLE’s tool for preclinical studies and the Downs and Black checklist for clinical studies. Results: Ten preclinical studies (223 animals) and 14 clinical studies (594 patients) were included. Preclinical results documented improvements at the cartilage histological and immunohistochemical evaluation and at the biomarkers level. Clinical studies confirmed the procedure’s safety, and the case series suggested satisfactory results in different joints in terms of symptoms and function improvement, with positive findings at the biomarker level. However, the randomized controlled trials did not document any clinical benefit, nor any changes in the imaging analysis. A large heterogeneity and overall poor quality were documented in both preclinical and clinical studies. Conclusions: There is an increasing interest in the use of adipose tissue-derived injectable products associated with PRP for the treatment of OA joints, with preclinical studies showing promising results with this combined approach. However, clinical studies did not confirm the benefits offered by PRP augmentation to adipose tissue-derived injectable products in patients affected by OA. https://eor.bioscientifica.com/view/journals/eor/9/11/EOR-24-0050.xmladipose tissuecartilageorthobiologicsosteoarthritisplatelet-rich plasma |
| spellingShingle | Simone Orazi Angelo Boffa Manuela Salerno Lucia Angelelli Stefano Zaffagnini Giuseppe Filardo Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence EFORT Open Reviews adipose tissue cartilage orthobiologics osteoarthritis platelet-rich plasma |
| title | Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence |
| title_full | Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence |
| title_fullStr | Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence |
| title_full_unstemmed | Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence |
| title_short | Adipose tissue-derived injectable products combined with platelet-rich plasma for the treatment of osteoarthritis: the promising preclinical results are not confirmed by the clinical evidence |
| title_sort | adipose tissue derived injectable products combined with platelet rich plasma for the treatment of osteoarthritis the promising preclinical results are not confirmed by the clinical evidence |
| topic | adipose tissue cartilage orthobiologics osteoarthritis platelet-rich plasma |
| url | https://eor.bioscientifica.com/view/journals/eor/9/11/EOR-24-0050.xml |
| work_keys_str_mv | AT simoneorazi adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence AT angeloboffa adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence AT manuelasalerno adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence AT luciaangelelli adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence AT stefanozaffagnini adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence AT giuseppefilardo adiposetissuederivedinjectableproductscombinedwithplateletrichplasmaforthetreatmentofosteoarthritisthepromisingpreclinicalresultsarenotconfirmedbytheclinicalevidence |